Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer
2011

Study of Phenoxodiol in Cancer Patients

Sample size: 6 publication Evidence: low

Author Information

Author(s): Jan B Howes, Paul L de Souza, Leanne West, Li Jiu Huang, Laurence G Howes

Primary Institution: Griffith University

Hypothesis

What are the pharmacokinetics of phenoxodiol following intravenous administration in patients with advanced cancer?

Conclusion

Phenoxodiol has a short plasma half-life, particularly in the free form, leading to a rapid attainment of steady state levels during continuous intravenous infusion.

Supporting Evidence

  • Phenoxodiol was administered to six patients with advanced cancer.
  • The pharmacokinetics were studied after both a single bolus and continuous infusion.
  • The study found that phenoxodiol has a short half-life and high clearance rates.

Takeaway

This study looked at how a new cancer drug, phenoxodiol, behaves in the body after being given through an IV. It found that the drug leaves the body quickly.

Methodology

A single center, open-label pharmacokinetic study involving six patients with metastatic cancer was performed, administering both a single intravenous bolus and a continuous intravenous infusion of phenoxodiol.

Potential Biases

Potential conflicts of interest due to funding and employment relationships with Novogen Pty Ltd.

Limitations

The study involved a small number of patients and examined only a limited dose range of phenoxodiol.

Participant Demographics

Six patients (3 males, 3 females) with metastatic cancer, mean age 61.2 years.

Digital Object Identifier (DOI)

10.1186/1472-6904-11-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication